Statins are inexpensive prescription oral medications that lower plaque-building cholesterol particles, used to prevent heart attacks and strokes. Trials show fewer such events and a modest survival gain, growing with longer, deeper cholesterol lowering; relative benefit appears similar at lower starting risk. Costs are mostly small: slightly higher blood sugar and diabetes diagnoses, mild muscle aches, minor liver enzyme changes, more bleeding strokes. Dementia, cancer or aging protection is unconfirmed. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL-C | <55 mg/dL very high risk, <70 high, <100 moderate | Efficacy |
| ApoB | <65 mg/dL very high risk, <80 high, <100 moderate | Particle number |
| ALT | 7–55 U/L; stop or reduce at ≥3× upper limit of normal | Liver safety check |
| CK | Women 26–192 U/L, men 39–308 U/L | Muscle safety check when symptoms appear |
| HbA1c | 4.0–5.6% | Safety check; statins raise blood sugar |
| hsCRP | JUPITER entry threshold ≥2.0 mg/L; track change from own baseline | Inflammation |
| Urinalysis (protein, blood) | Negative | Safety check on high-dose rosuvastatin |
| Kidney function | Not specified in the ER | Baseline reference |
| Fasting glucose | Not specified in the ER | Paired with HbA1c |
| Bilirubin | Not specified in the ER | Paired with ALT if elevated |
Cadence: Baseline panel before starting; lipids from 4 weeks after starting or changing dose, then every 3–12 months, with apoB alongside; HbA1c at 3–12 months, then yearly; ALT and CK only when symptoms or interacting drugs arise.